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Prognostic Significance of Angiogenesis by Chalkley Counting  
in Node Negative Cancer of the Ampulla of Vater 
Angiogenesis is essential for tumor growth and metastasis. Currently, the Chalkley assay 
with CD34 immunostaining is the proposed standard method for angiogenesis 
quantification in solid tumor sections. The purpose of this study was to evaluate the 
expression of CD34 and its prognostic significance using the Chalkley method in node 
negative carcinoma of the ampulla of Vater. Between January 1997 and December 2006, 
56 node negative patients who had curative resection for carcinoma of the ampulla of 
Vater were retrospectively reviewed. The Chalkley count was expressed as the mean value 
of the three counts for each tumor and further divided into two groups according to the 
mean value of the Chalkley count: low  < 4 or high  ≥ 4. The mean Chalkley count value 
was 4.0 (± 3.1). In the low Chalkley group, the 1- and 3-yr recurrence rates were 18.3%, 
47.6% respectively; in the high Chalkley group, the 1- and 3-yr recurrence rates were 
26.5% and 60.6% respectively. Only high Chalkley count had statistical significance as a 
factor in recurrence of node negative ampulla of Vater carcinoma. Assessment of 
angiogenesis may have an important role in the prognostic evaluation of node negative 
cancer of the ampulla of Vater.
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INTRODUCTION
Carcinomas of the ampulla of Vater have a higher resection rate, 
lower recurrence rate and more favorable prognosis than other 
malignant tumors of the periampullary region (1, 2). However, 
tumor recurrences remain frequent problems after surgical treat-
ment of carcinomas of the ampulla of Vater. In ampulla of Vater 
cancer, the important prognostic factors include the TNM stage, 
cell differentiation and histologic type. We often encounter a 
substantial number of patients whose prognosis is not consis-
tent with the TNM stage, and other prognostic criteria must be 
used in place of the TNM staging system that is widely utilized 
at present. 
  Angiogenesis is the development of new vessels from pre- 
existing vessels, and is essential for tumor growth and metasta-
sis (3). The prognostic value of angiogenesis in various types of 
carcinoma has been widely studied since Weidner et al. (4) re-
ported that high vascular scores were associated with distant 
metastasis. Currently, the Chalkley assay with CD 34 immuno-
histostaining is the proposed standard method for angiogenesis 
quantification in solid tumor sections, according to an interna-
tional consensus report (5). Many studies have reported that the 
angiogenesis is a powerful prognostic factor in breast cancer (4, 
6, 7). There are no previous studies on angiogenesis in ampulla 
of Vater carcinoma. 
  Therefore, the purpose of this study was to evaluate the expres-
sion of CD34 and its prognostic significance using the Chalkley 
method in node negative carcinoma of the ampulla of Vater. 
MATERIALS AND METHODS
Patients
Between January 1997 and December 2006, 96 patients received 
a radical resection for carcinoma of the ampulla of Vater at Sev-
erance Hospital, Yonsei University College of Medicine, Seoul, 
Korea. 
  Among these 96 patients, 10 were excluded based on the cri-
teria that tissue samples were not well preserved, clinicopatho-
logic data was incomplete or follow-up was lost. As a result, 86 
patients who had undergone curative resection were retrospec-
tively reviewed. 
  Among the 86 patients described above, 56 patients were 
node negative and 30 were node positive. Ultimately, 56 node 
negative patients were enrolled in this study. The patients were 
followed closely until December 31, 2010. All patients were fol-
lowed up for more than six months. Park JS, et al.  •  Angiogenesis in Ampulla of Vater Cancer
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Immunohistochemical staining
The 5 μm serial sections of each block were adhered to poly-L-
lysin covered slides, and incubated at 62°C for 60 min. After par-
affin elimination with xylene and staged ethyl alcohol dehydra-
tion, the sections were heated in a microwave containing a 10 mM 
citrate buffer (pH 6.0) solution for 15 min. The primary antibody 
used against CD 34 was from clone QBEND/10 (NovoCastra, 
Newcastle-upon-Tyne, UK). The procedure has been described 
in detail elsewhere (8). 
Evaluation of angiogenesis by the Chalkely counting 
Angiogenesis in cancer of the ampulla or Vater was evaluated 
by two pathologists who had no information regarding clinical 
outcomes. We evaluated tumor vascularization using the Chalke-
ly method as described by Fox et al. (9). Briefly, the CD 34 stained 
sections were scanned at low magnification for the most vascu-
lar area within the tumor section, and three hotspot areas were 
chosen subjectively. A 25-point Chalkey eyepiece graticule was 
applied to each hot spot at a higher magnification (X 200 mag-
nification, corresponding to an area of 0.196 mm
2), and orient-
ed to permit the maximum number of points to hit on or within 
the immunohistochemically stained microvessels. The Chalk-
ley count was expressed as the mean value of the three counts 
for each tumor and further divided into two groups according 
to the mean value of the Chalkley count: low  < 4 or high  ≥ 4.   
Statistical analysis
To examine the correlation between the Chalkley count and clin-
icopathologic variables, we used the chi-square test. For surviv-
al analysis, we performed a Kaplan-Meier survival curve based 
on the log-rank test using the SPSS version 11.0. Overall survival 
was defined as the time interval between the date of surgery and 
the date of death from the cancer or last follow-up date. Recur-
rence-free survival was defined by the time interval between 
the date of surgery and the date of recurrence or last follow-up 
date. Multivariate survival analysis was performed using a step-
wise forward inclusion algorithm of Cox proportional hazard 
model. P values of less than 0.05 were considered to be statisti-
cally significant.
Ethics statement 
This study was approved by the institutional review board of 
Yonsei University for retrospective chart review and data collec-
tion (3-2011-0261). Informed consent was exempted by the board.
RESULTS
Patients characteristics
A total of 56 node negative patients were selected for this study. 
The mean age was  56.3 yr (± 10.1 yr) and the group was consist-
ed of 31 men and 25 women. All patients underwent pancreati-
coduodenectomy (or pylorus preserving pancreaticoduodenec-
tomy) and dissection of the lymph nodes in the hepatoduode-
nal ligament, the common hepatic artery and the celiac axis. 
Relation of CD34 expression to clinicopathologic factors 
The mean Chalkley count was 4.0 (± 3.1). Thirty-six of 56 pa-
tients were categorized into the low (< 4), and 20 of 56 patients 
were into the high expression group (≥ 4). 
  A high Chalkley count was significantly associated with the 
depth of tumor invasion and perineural invasion. However, the 
Chalkley count was not significantly correlated with sex, age, 
tumor size or cell differentiation (Table 1).
Table 1. Correlation between angiogenesis and clinicopathological characteristics in 
ampulla of Vater cancer 
Variables
Chalkley count 
P values Low (< 4)  
N = 36
High (≥ 4)  
N = 20
Sex
   M
   F
 
20
16
 
11
  9
0.968
Age (yr)
   < 60
   ≥ 60
 
22
14
 
14
  6
0.506
Tumor size (cm)
   < 2
   ≥ 2
 
18
18
 
13
  7
0.276
Perineural invasion 
   No 
   Yes
 
27
  9
 
15
  5
0.001
Gross type 
   Polypoid 
   Ulceration 
 
24
12
 
12
  8
0.618
Differentiation
   Well differentiated 
   Mod/poor differentiated
 
13
23
 
12
  8
0.085
Invasion depth
   T1/T2
   T3/T4
 
26
10
 
  9
11
0.044
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Fig. 1. Cumulative survival rate in node negative ampulla of Vater carcinoma.Park JS, et al.  •  Angiogenesis in Ampulla of Vater Cancer
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Survival and disease free survival analysis 
For the 56 node negative patients who received radical resec-
tion for ampulla of Vater cancer, the 3- and 5-yr overall survival 
rate were 47.2 % and 44.1%, respectively (Fig. 1).
  The 1- and 3-yr disease free survival (DFS) was 79.8% and 
42.9% respectively (Fig. 2). In univariate analysis, high Chalkley 
count showed statistical significance factors as DFS in node 
negative ampulla of Vater carcinoma (Table 2). In multivariate 
analysis, only high Chalkley count was identified as an indepen-
dent significance factors as DFS in node negative ampulla of 
Vater carcinoma (Table 3). In the low Chalkley group, the 1- and 
3-yr DFS were 81.7% and 52.4% respectively; in the high Chalk-
ley group, the 1- and 3-yr DFS were 73.5% and 39.4% respec-
tively (Fig. 3).
DISCUSSION
Angiogenesis is the formation of new vessels from the existing 
vascular network, and is essential for tumor growth and meta-
static capacity. Neovascularization of a tumor is required to pro-
vide essential nutrients beyond the limit of simple diffusion, and 
to allow for tumor growth beyond 2 μL (10). It is well known that 
the degree of angiogenesis is associated with tumor progression 
in breast cancer, lung cancer and prostate cancer (7, 11-13). This 
suggests that angiogenesis is a significant prognostic indicators 
in patients with carcinoma of the ampulla of Vater. However, the 
role of angiogenesis in this cancer remains unclear. 
  The Chalkley count is the number of grid point that hit stained 
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Fig. 2. Disease free survival (DFS) rate in node negative ampulla of Vater carcinoma. 
Table 2. Univariate survival and recurrence analysis of clinicopathologic characteristics in 56 patients with node negative ampulla of Vater cancer
Variables
Survival rate (%)
P values
Disease free survival rates (%)
P values
3 yr 5 yr  1 yr 3 yr
Sex
   M
   F
 
61.7
57.4
 
57.3
57.4
0.867  
83.6
85.4
 
49.5
35.4
0.799
Age (yr)
   < 60
   ≥ 60
 
64.9
50.6
 
60.8
50.6
0.470  
79.9
70.0
 
59.7
34.3
0.818
Tumor size (cm)
   < 2
   ≥ 2
 
62.2
57.6
 
62.2
51.2
0.569  
77.8
81.9
 
38.2
45.5
0.839
Gross type 
   Polypoid 
   Ulceration
 
65.8
56.2
 
65.8
52.2
0.290  
78.6
50.5
 
60.8
39.5
0.491
Perineural invasion 
   No 
   Yes 
 
67.2
55.7
 
67.2
51.7
0.193  
53.6
70.0
 
48.6
39.2
0.620
Differentiation
   Well differentiated
   Mod/poorly differentiated
 
57.1
77.9
 
51.9
31.2
0.187  
85.7
76.0
 
36.0
56.6
0.884
Tumor invasion 
   T1/T2
   T3/T4
 
59.5
60.3
 
59.5
54.2
0.557  
77.1
84.6
 
47.1
35.7
0.823
Chalkley count 
   Low (< 4)
   High (≥ 4)
 
73.1
53.1
 
65.0
53.1
0.427  
81.7
73.5
 
52.4
49.4
0.047
Table 3. Multivariate recurrence analysis of clinicopathologic characteristics in 56 pa-
tients with node negative ampulla of Vater cancer
Variables
P 
values
Odds  
ratio
Confidence interval 
(95%)
Lower Upper
Ulceration type  0.430 1.568 0.513   4.793
Large tumor size (≥ 2 cm) 0.743 1.195 0.413   3.451
Mod/Poorly differentiated 0.369 3.059 0.267 35.088
Depth of invasion (T3/T4) 0.352 1.699 0.556   5.193
Presence of perineural invasion  0.609 0.724 0.210   2.497
High Chalkley count (≥ 4) 0.032 3.364 1.107 10.218Park JS, et al.  •  Angiogenesis in Ampulla of Vater Cancer
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vessels, taken as the average from the assessment of three hot 
spots. Quantifying angiogenesis using the Chalkley method has 
been recommended in an international consensus report (5). 
This method has been thought to have an advantage in that it 
improves the objectivity of evaluation by eliminating the depen-
dency on an observer in microvessel density measuring.  How-
ever, an observer is still necessary for the selection of hotspot 
areas for microvessel quantification. 
  In the immunohistochemical angiogenesis technique, anti-
bodies to CD 34, CD31 and the von Willebrand factor (factor VIII) 
have been used to detect vascular structures. Among these anti-
bodies, CD34 was chosen for this study, as it has been shown to 
give more immunohistochemical staining of microvessels than 
either CD31 or factor VIII (14). CD34 is a cell surface protein 
that is selectively expressed by vascular endothelial cells and 
has been suggested as a standard method for measuring angio-
genesis in solid tumor sections in an international consensus 
report (5). 
  In this study, angiogenesis was associated only with tumor 
invasion. Angiogenesis as evaluated with the Chalkley method 
was not associated with other tumor systems except tumor in-
vasion, which was a finding very similar to many previous ovar-
ian cancer studies using different evaluation method (15, 16). 
Presumably, our results might have been caused by the follow-
ing reasons: first, for technical reasons, the difference in the time 
of ischemic onset due to the time gap between tissue resection 
and freezing might have affected the immunohistochemical   
results (17, 18); second, a pathologic diagnosis of ampullar of 
Vater cancer is usually made during an endoscopic biopsy per-
formed prior to a radical operation. As a result, normal wound 
healing procedure is initiated and characterized by a substan-
tial neovascular response. These regions might contain a large 
number of microvessels, and may be mistakenly selected as the 
designated hotspots. Identification of the regions of neovascu-
larization associated with prior endoscopic biopsy sites must 
be excluded as potential regions of maximum microvessel den-
sity. Therefore, further studies are warranted to examine angio-
genesis in a large group of ampulla of Vater cancer patients. 
  Most studies evaluating the association between tumor pro-
gression and angiogenesis have reported their results after divid-
ing the patient population into two groups on the basis of aver-
age microvessel count cutoff. Nakayama et al. (19) reported dif-
ferent features of angiogenesis between ovarian and breast car-
cinoma and found that angiogenesis in ovarian carcinoma was 
lower than in breast carcinoma as evaluated by intratumoural 
microvessel density; we found that the median Chalkley count 
was lower than that of breast cancer. Our data were compatible 
with previous reports, as increasingly aggressive behavior was 
shown in node negative cancer of the ampullar of Vater ranging 
from low to high microvessel counts. A Cox’s proportional haz-
ards analysis revealed a statistically significant association be-
tween increasing microvessel counts and increased tumor re-
currence. However, angiogenesis might not be an all or nothing 
phenomenon with respect to tumor growth. Progressive increases 
in aggressive behavior exhibited by tumors may be associated 
with increasing extents of angiogenesis. 
  The role of postadjuvant chemotherapy in patients with node 
negative ampulla of Vater cancer is controversial. We have shown 
that elevated Chalkley counts (> 4) are related to disease recur-
rence in patients with node negative tumors. Hence, the group 
of node-negative patients with Chalkley counts of  > 4 is of poten-
tial interest for evaluating the effects of systemic adjuvant treat-
ment. Furthermore, the vessel estimate may be suitable for strat-
ification for antiangiogenic treatment.
  In conclusion, assessment of angiogenesis may have an im-
portant role in the prognostic evaluation of node negative am-
pulla of Vater cancer. Investigation of the mechanism of angio-
genesis in cancer of the ampulla of Vater may provide further 
prognostic information and help to rationalize therapy. These 
markers may be useful in selecting patients for chemothera-
peutic treatment protocols including the use of antiangiogenic 
agents. 
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